Maria-Helena Perez

Dr. Maria-Helena Perez

women-mother-child, University Hospital of Lausanne, Lausanne, Vaud, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
LSLuregn J. Schlapbach
Luregn J. Schlapbach
MAMaya C. Andre
Maya C. Andre
SGSerge Grazioli
Serge Grazioli
NSNina Schöbi
Nina Schöbi
NRNicole Ritz
Nicole Ritz
PRPeter C. Rimensberger
Peter C. Rimensberger
Background: Following the spread of the coronavirus disease 2019 (COVID-19) pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C). In the absence of trials, evidence for treatment remains scarce.Purpose: To develop best practice recommendations for the diagnosis and treatment of children with PIMS-TS in Switzerland. It is acknowledged that the field is changing rapidly, and regular revisions in the coming months are pre-planned as evidence is increasing.Methods: Consensus guidelines for best practice were established by a multidisciplinary group of Swiss pediatric clinicians with expertise in intensive care, immunology/rheumatology, infectious diseases, hematology, and cardiology. Subsequent to literature review, four working groups established draft recommendations which were subsequently adapted in a modified Delphi process. Recommendations had to reach >80% agreement for acceptance.Results: The group achieved agreement on 26 recommendations, which specify diagnostic approaches and interventions across anti-inflammatory, anti-infectious, and support therapies, and follow-up for children with suspected PIMS-TS. A management algorithm was derived to guide treatment depending on the phenotype of presentation, categorized into PIMS-TS with (a) shock, (b) Kawasaki-disease like, and (c) undifferentiated inflammatory presentation.Conclusion: Available literature on PIMS-TS is limited to retrospective or prospective observational studies. Informed by these cohort studies and indirect evidence from other inflammatory conditions in children and adults, as well as guidelines from international health authorities, the Swiss PIMS-TS recommendations represent best practice guidelines based on currently available knowledge to standardize treatment of children with suspected PIMS-TS. Given the absence of high-grade evidence, regular updates of the recommendations will be warranted, and participation of patients in trials should be encouraged.

1 April 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
ABAnnika Reintam Blaser
Annika Reintam Blaser
JGJan Gunst
Jan Gunst
CICarole Ichai
Carole Ichai
MCMichael P. Casaer
Michael P. Casaer
CBCarina Benstöm
Carina Benstöm
MBMette M. Berger
Mette M. Berger

1 April 2016 in Clinical Nutrition
Verified
Journal Article
Closed access
CCCorinne Jotterand Chaparro
Corinne Jotterand Chaparro
JDJocelyne Laure Depeyre
Jocelyne Laure Depeyre
DLDavid Longchamp
David Longchamp
Maria-Helena PerezMaria-Helena Perez
Maria-Helena Perez
PTPatrick Taffé
Patrick Taffé
JCJacques Cotting
Jacques Cotting

25 May 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
PGPedro D. Wendel Garcia
Pedro D. Wendel Garcia
HAHernán Aguirre-Bermeo
Hernán Aguirre-Bermeo
PBPhilipp K. Buehler
Philipp K. Buehler
MAMario Alfaro-Farias
Mario Alfaro-Farias
BYBernd Yuen
Bernd Yuen
FRFerran Roche-Campo
Ferran Roche-Campo
Background: Uncertainty about the optimal respiratory support strategies in critically ill COVID-19 patients is widespread. While the risks and benefits of noninvasive techniques versus early invasive mechanical ventilation (IMV) are intensely debated, actual evidence is lacking. We sought to assess the risks and benefits of different respiratory support strategies, employed in intensive care units during the first months of the COVID-19 pandemic on intubation and intensive care unit (ICU) mortality rates. Methods: Subanalysis of a prospective, multinational registry of critically ill COVID-19 patients. Patients were subclassified into standard oxygen therapy ≥10 L/min (SOT), high-flow oxygen therapy (HFNC), noninvasive positive-pressure ventilation (NIV), and early IMV, according to the respiratory support strategy employed at the day of admission to ICU. Propensity score matching was performed to ensure comparability between groups. Results: Initially, 1421 patients were assessed for possible study inclusion. Of these, 351 patients (85 SOT, 87 HFNC, 87 NIV, and 92 IMV) remained eligible for full analysis after propensity score matching. 55% of patients initially receiving noninvasive respiratory support required IMV. The intubation rate was lower in patients initially ventilated with HFNC and NIV compared to those who received SOT (SOT: 64%, HFNC: 52%, NIV: 49%, p = 0.025). Compared to the other respiratory support strategies, NIV was associated with a higher overall ICU mortality (SOT: 18%, HFNC: 20%, NIV: 37%, IMV: 25%, p = 0.016). Conclusion: In this cohort of critically ill patients with COVID-19, a trial of HFNC appeared to be the most balanced initial respiratory support strategy, given the reduced intubation rate and comparable ICU mortality rate. Nonetheless, considering the uncertainty and stress associated with the COVID-19 pandemic, SOT and early IMV represented safe initial respiratory support strategies. The presented findings, in agreement with classic ARDS literature, suggest that NIV should be avoided whenever possible due to the elevated ICU mortality risk.

1 May 2021 in Clinical Nutrition
Verified
Journal Article
Open access
MBM.M. Berger
M.M. Berger
OAO. Appelberg
O. Appelberg
ARA. Reintam-Blaser
A. Reintam-Blaser
CIC. Ichai
C. Ichai
OJO. Joannes-Boyau
O. Joannes-Boyau
MVMarina Verçoza Viana
Marina Verçoza Viana
Hypophosphatemia (HypoP) is associated with organ dysfunction and mortality. Despite its potential severe consequences, HypoP remains poorly characterized in terms of real prevalence and timing of onset. The primary objective was to determine the prevalence of HypoP defined as blood phosphate <0.8 and < 0.65 mmol/l on one particular day at international level. One-day point prevalence survey conducted by the Section of Metabolism, Endocrinology and Nutrition (MEN) of the European Society of Intensive Care Medicine (ESICM) during week 11-2020. In total, 56 adult and 4 paediatric ICUs, from 22 countries participated: 41 ICUs were mixed medico surgical, the 19 others being cardiac, medical or surgical. Phosphate measurements were performed daily in 21 ICUs, and 1-3 times per week in 39 ICUs. On D-Day 909 patients (883 adults) were present and 668/883 (75.7%) had serum/plasma phosphate determined, revealing a HypoP in 103 (15.4%) patients aged 62 [18 to 85] years. Of those, 49 patients presented phosphate <0.65 mmol/l: cases of hypophosphatemia were detected at any time of patient's ICU stay. No HypoP was observed in children. A treatment protocol existed only in 41.1% of adult ICUs, independently of ICU type, or size. Only 41/98 of the HypoP patients (29/41 of patients with phosphate <0.65 mmol/l) were receiving phosphate. HypoP is present at least in 15.4% of ICU patients, and may occur at any time during the ICU stay. The absence of phosphate repletion protocols in 60% of participating ICUs is an unexpected finding, and confirms the necessity for the development of ICU phosphate protocols and guidelines. NCT04201899.

3 February 2023 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
TWTatjana Welzel
Tatjana Welzel
AAAndrew Atkinson
Andrew Atkinson
NSNina Schöbi
Nina Schöbi
MAMaya C Andre
Maya C Andre
DBDouggl G N Bailey
Douggl G N Bailey
SFSaul N Faust
Saul N Faust